Contact
searchSearch
HMP Global
CIO2022 Highlights

Edward Kim, MD, FSIR, Discusses the Updated Clinical and Dosimetric Recommendations for Y-90 Glass Microspheres in HCC

Edward Kim, MD
10/26/2022

Introduction

Dr Edward Kim discusses his CIO2022 abstract, "Updated Clinical and Dosimetric Recommendations for Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma." 

CLICK HERE TO READ THE FULL ABSTRACT AND VIEW POSTER

Video


Related Content

VDM logo
SIO 2026
Abstracts Presented at SIO 2026 Highlight Advances in Y-90 Radioembolization
03/02/2026
Laura Simson, MA
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
The yttrium-90 (Y-90) abstracts...
03/02/2026
Vascular Disease Management
VDM logo
Analysis
Artificial Intelligence Advances in Interventional Oncology: Year in Review
02/23/2026
Laura Simson, MA
02/23/2026
Vascular Disease Management
FIgure 2B
Case Study
Embolization of Primary and Metastatic Hepatic Tumors Using the Embrace™ Hydrogel Embolic System: Case Studies
09/26/2025
Edgar St. Amour, MD; Nadine Abi-Jaoudeh, MD
These cases were part of the Instylla HES Hypervascular Tumor Pivotal Study to evaluate the safety and effectiveness of Embrace HES compared with standard of care TAE or TACE.
These cases were part of the Instylla HES Hypervascular Tumor Pivotal Study to evaluate the safety and effectiveness of Embrace HES compared with standard of care TAE or TACE.
These cases were part of the...
09/26/2025
Vascular Disease Management
TheraSphere webinar image
Webinar
Evidence to Impact: Treating Large HCC Tumors with TheraSphere™ Y-90 Glass Microspheres
09/17/2025
Join Dr. Tyler Sandow for an expert-led discussion on how TheraSphere™ Y-90 is redefining treatment for large hepatocellular carcinoma (HCC) tumors. This session will highlight the latest clinical data, explore the importance of radiation per...
Join Dr. Tyler Sandow for an expert-led discussion on how TheraSphere™ Y-90 is redefining treatment for large hepatocellular carcinoma (HCC) tumors. This session will highlight the latest clinical data, explore the importance of radiation per...
Join Dr. Tyler Sandow for an...
09/17/2025
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

Abdominal Aortic Aneurysm
Data Presented on Two-Year Proximal Neck Dynamics From First-in-Human Study of Abdominal Aortic Aneurysm Treatment
06/26/2026
Tempe, AZ – June 25, 2026 – Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational...
Tempe, AZ – June 25, 2026 – Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational...
Tempe, AZ – June 25, 2026 –...
06/26/2026
Vascular Disease Management
New Guiding Sheath
Volante™ Steerable Guiding Sheath Now Available in US
06/23/2026
Key Highlights  The Volante Steerable Guiding Sheath is designed to facilitate intracardiac, renal and peripheral placement of diagnostic and therapeutic devices.  With five different lengths and six different French sizes,...
Key Highlights  The Volante Steerable Guiding Sheath is designed to facilitate intracardiac, renal and peripheral placement of diagnostic and therapeutic devices.  With five different lengths and six different French sizes,...
Key Highlights  The...
06/23/2026
Vascular Disease Management
Clinical Trials
SYMPHONY-PE Trial Post-Hoc Analysis Suggests Early Thrombectomy May Improve Key Measures of Heart Recovery in Intermediate-Risk Pulmonary Embolism
06/18/2026
Treating patients within 12 hours of diagnosis may be associated with greater improvement in acute hemodynamic and right ventricle measures compared to treatment after 12 hours, with similar safety outcomes between groups.
Treating patients within 12 hours of diagnosis may be associated with greater improvement in acute hemodynamic and right ventricle measures compared to treatment after 12 hours, with similar safety outcomes between groups.
Treating patients within 12...
06/18/2026
Cath Lab Digest
Team Communication
IB Nimble 2 Adds In-App DICOM Viewing for Real-Time Multidisciplinary Collaboration
06/17/2026
The most notable enhancement is the ability to view medical images directly within the app. This long-awaited feature enables care teams to review imaging in real time.
The most notable enhancement is the ability to view medical images directly within the app. This long-awaited feature enables care teams to review imaging in real time.
The most notable enhancement is...
06/17/2026
Cath Lab Digest
CE Mark
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT
06/16/2026
The THUNDERBOLT™ Computer Assisted Vacuum Thrombectomy (CAVT™) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal.
The THUNDERBOLT™ Computer Assisted Vacuum Thrombectomy (CAVT™) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal.
The THUNDERBOLT™ Computer...
06/16/2026
Cath Lab Digest
FDA Clearance
Penumbra’s THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
06/15/2026
Powered by the Penumbra ENGINE™, THUNDERBOLT introduces modulated aspiration to Penumbra’s neuro thrombectomy portfolio, offering advanced CAVT technology designed to detect, fatigue, and completely ingest clot at the site of the occlusion. 
Powered by the Penumbra ENGINE™, THUNDERBOLT introduces modulated aspiration to Penumbra’s neuro thrombectomy portfolio, offering advanced CAVT technology designed to detect, fatigue, and completely ingest clot at the site of the occlusion. 
Powered by the Penumbra ENGINE™,...
06/15/2026
Cath Lab Digest
Veterans With PAD
Department of Veteran Affairs Referrals for Peripheral Artery Disease Nearly Triples Over the Past Five Years
06/15/2026
More than 180,000 veterans receive care for PAD in Department of Veterans Affairs hospitals.
More than 180,000 veterans receive care for PAD in Department of Veterans Affairs hospitals.
More than 180,000 veterans...
06/15/2026
Cath Lab Digest
Thrombolex, Inc.
Thrombolex, Inc. Names Michael Tutera Chief Executive Officer
06/12/2026
New Britain, PA, June 15, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, June 15, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, June 15, 2026 –...
06/12/2026
Vascular Disease Management
PAD Guidelines
VAM26: Complete Adherence to Guideline-Directed Care Associated with Decreased Serious Limb Complications at Two Years
06/10/2026
“Our study was designed to establish the evidence of a comprehensive multidisciplinary approach before considering surgical intervention,” said Dr. Richard Shi, vascular surgery resident at the Medical University of South Carolina. “Too...
“Our study was designed to establish the evidence of a comprehensive multidisciplinary approach before considering surgical intervention,” said Dr. Richard Shi, vascular surgery resident at the Medical University of South Carolina. “Too...
“Our study was designed to...
06/10/2026
Cath Lab Digest
Thrombectomy
First-in-Human Clinical Success with Novel Mechanical Thrombectomy System
06/09/2026
"The V-PULSE system removed significant clot burden and provided immediate visual confirmation of thrombus capture through its integrated filtration technology," said Makmood Razavi, MD.
"The V-PULSE system removed significant clot burden and provided immediate visual confirmation of thrombus capture through its integrated filtration technology," said Makmood Razavi, MD.
"The V-PULSE system removed...
06/09/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use